You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Photoacoustic CT for Preclinical Molecular Imaging

    SBC: OPTOSONICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this collaborative research project is to commercialize a prototype photoacoustic computed-tomography (PCT) scanner for conducting preclinical molecular imaging. This scanner has been developed by OptoSonics with funding from a Fast Track SBIR grant from the National Cancer Institute (R44-CA-102891) and additional private funding fro ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Self Assembling High Affinity Peptides for Point of Care Drug-Device Combinations

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Infection surrounding metal implants is a common and sometimes devastating cause of implant failure in a number of fields including oral, craniomaxillofacial (CMF), orthopedic, and cardiovascular surgery. These infections, which arise from the establishment of biofilms on device surfaces, not only necessitate new surgeries but in themselves present a significan ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Commercialization of Human Mesothelial Cells for Research

    SBC: Zen-Bio, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Mesothelial cells have been found to be pivotal in tumor metastasis, peritoneal dialysis, and inflammatory response. These cells are specialized epithelial cells that line the peritoneal, pericardial, and pleural cavities and internal organs presenting a barrier to invading organisms and physical damage. Ovarian tumor attachments occur through cancer cells bind ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Formulations for Injectable Growth Factors

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 6.3 million fractures occur each year in the United States alone (Praemer et al. 1999) and approximately 15% of fractures exhibit delayed or impaired healing. The clinical applications currently used to treat delayed fracture require open surgery to insert an autologous bone graft. If open surgery is confounded by co-morbidity or is deemed otherwise undes ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic for the Negative Symptoms of Schizophrenia

    SBC: Darpharma, Inc.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Schizophrenia affects roughly 1% of the world's population, with more than two million Americans afflicted in any given year, and an estimated 30-50 million people worldwide. Treatment with available antipsychotic medications often effectively attenuates the positive symptoms of schizophrenia without improvement in the negative symptoms or cognitive deficits. F ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Antibiotic-binding peptides for biofilm prevention on ventriculoperitoneal shunts

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Ventriculoperitoneal (VP) shunts are used to treat pediatric and neonatal hydrocephalus in severe cases, representing approximately 1/3rd of affected infants. Due to the high susceptibility for infection and mechanical breakdown, the failure rate of VP shunts is around 30-40%. A need therefore exists to improve infection prevention for this procedure, likely by ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Growth Factor Coated Sutures for Improved Tendon Repair

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Of the nearly 5 million patients who visit a physician for tendon pain each year in the US, approximately 200,000 go on to have a surgical repair. And while surgical repair has a high-rate of symptom relief, recovering patients are routinely immobilized for several months. Increased tendon strength, during shorter time courses has been reported in animal models ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Synthesis and Evaluation of a Novel Anti-HIV Agent

    SBC: Kucera Pharmaceutical Company            Topic: N/A

    The long-term goal of this research is to develop a drug that is safe and effective against drug-resistant human immunodeficiency virus (HIV) infection. Several challenges confront current anti-HIV chemotherapy. The frequency of drug-resistant and multidrug-resistant HIV-1 is increasing. Toxicities associated with current HIV medications often result in the discontinuation of these therapies. Phys ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Electrochemical RT Activity Assay for Measuring HIV Load

    SBC: ALDERON BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): To address the urgent need for better treatment and diagnostic testing of HIV infected people in resource-limited settings, we propose in this Phase II SBIR to further develop an electrochemical testing system (eSystem) developed by Alderon Biosciences, Inc. for determinations of HIV viral load in clinical samples. Alderon's long-term goal is to produce, valida ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes

    SBC: VASCULAR PHARMACEUTICALS            Topic: N/A

    DESCRIPTION (provided by applicant): The long term objective of the proposed studies is to develop a monoclonal antibody that can be administered safely to patients with diabetes that will inhibit atherosclerosis. Insulin-like growth factor-I has been implicated in the initiation of the proliferative phase of atherosclerotic lesion development but inhibiting IGF-I receptor activity may lead to tox ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government